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Abstract 
Introduction: During the COVID-19 pandemic, most of the
published reports on COVID-19 emphasized that health care
workers (HCWs) get infected more than the general population
representing one of the most vulnerable groups. However, that the
real percentage of HCWs infected by SARS-CoV2 in Egypt
remains unknown. The researchers conducted the current study to
assess seroprevalence of SARS-CoV-2 IgG among HCWs work-
ing in a hospital with no SARS-CoV-2 patients, and to identify the
potential factors associated with SARS-CoV2 IgG seropositivity. 
Design and Methods: The current study is a cross-sectional
study carried out among 455 HCWs at Cairo University Hospital.
The researchers administered a questionnaire shortly before the
SARS-CoV-2 rapid test is performed using closed-ended question
format to obtain information on demographic data of the study
participants including age, sex, specialty, clinical information
including questions about medical conditions, and. history of pre-
vious exposure with a confirmed or suspected case of COVID-19,
and history of COVID-19- compatible symptoms during the pre-
vious 14 days (cough, sore throat, runny nose, fatigue, shortness
of breath, fever, headache, vomiting, diarrhea, anosmia, ageusia,
and chills). 
Results: We screened 455 HCWs for SARS-CoV-2 antibodies,
31.4% were in the high-risk group, and 68.6% in the low-risk
group. The overall IgG seroprevalence was, 36 (7.9%) (95% CI
5.8 to 10.8). The IgG seroprevalence was significantly higher in
low-risk group 11% (35/312) versus high-risk group 0.7% (1/143,
p<0.001. 
Conclusion: Low seropositivity rates for SARS-CoV-2 among
HCWs is suggestive of lack of immunity and we are still far from
herd immunity.
Introduction
During Coronavirus Disease-2019 (COVID-19) pandemic,
most of the published reports on COVID-19 emphasized that
health care workers (HCWs) get infected more than the general
population, representing one of the most vulnerable groups.1,2
According to Keeling et al.,3 HCWs represent 10% of overall
cases and often more than 10% of any hospital’s personnel are
commonly infected. Unlike Severe Acute Respiratory Syndrome
(SARS) or the Middle East Respiratory Syndrome (MERS),
COVID-19 has a lower mortality rate.2 Despite this lower mortal-
ity for Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) the causative agent for COVID-19, its long incu-
bation period resulted in a significant number of asymptomatic
infected individuals.4 A study done at the University of Cambridge
in a large United Kingdom teaching hospital revealed that 3% of
HCWs in the asymptomatic screening group tested positive for
SARS-CoV-2.5 Another study conducted among HCWs at a clinic
in Chile. revealed that a 3.4% of positivity in asymptomatic
HCWs.6 
Given that the real percentage of HCWs infected by SARS-
CoV2 in Egypt remains unknown, and in response to the increased
number of infected and deceased HCWs in Egypt, the researchers
conducted the current study to assess the seroprevalence of SARS-
CoV-2 IgG among HCWs working in a hospital with no SARS-
CoV-2 patients, and to identify the potential factors associated
with SARS-CoV-2 IgGs. 
Design and Methods
Study design, setting, and population
The current study is a cross-sectional study carried out among
HCWs at Cairo University Hospital. The researchers defined the
study population as those HCWs who deliver care and services to
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patients, including physicians and nurses. Inclusion criteria includ-
ed being an adult (>18 years) working at Cairo University
Hospital. Exclusion criteria included: a) absenteeism from the
workplace in the last 30 days, retirement, or end-of-contract, and
working in a COVID hospital.
From a total number of 700 HCWs, 600 were eligible to take
part in the study. We recruited 455, yielding a participation rate of
75%. All participants had worked at Cairo University Hospital for
at least one month before study enrollment and were asymptomatic
at the point of study recruitment. HCWs who were previously
diagnosed with COVID-19 were excluded from the study. We
divide health care workers into high risk and low-risk groups.
High-risk HCWs are defined as those who are dealing with aerosol
generating procedure pulmonary and included three departments
(anesthesia, critical care, and pulmonary care). Low risk HCWs are
those who are not involved in aerosol generating procedures.7
Procedures and data collection 
Serum collection and self-administered questionnaire
Before serum collection, the researchers used an online short
pre-screener questionnaire to determine the eligible HCWs and
exclude those with history of confirmed COVID-19 infection. It
included the following questions: name, email address, mobile
phone, specialty, the most suitable day for sample collection, and
the history of confirmed COVID-19.
After that, the researchers administered a questionnaire shortly
before the SARS-CoV-2 rapid test is performed using closed-
ended question format to obtain information on:
a. Demographic data of the study participants including age,
sex, specialty,
b. Clinical information including questions about medical con-
ditions (chest diseases, cardiovascular diseases, diabetes, etc.), sur-
gical history, medication intake such as (anticoagulant, immuno-
suppression, chemotherapy, steroids, antiepileptic, and vitamins),
and smoking history,
c. History of previous exposure with a confirmed or suspected
case of COVID-19, and history of COVID-19- compatible symp-
toms during the previous 14 days (cough, sore throat, runny nose,
fatigue, shortness of breath, fever, headache, vomiting, diarrhea,
anosmia, ageusia, and chills).
The questionnaire was based on Health workers exposure risk
assessment and management in the context of COVID-19 virus.8
Detecting serum IgG against SARS-CoV-2
Samples were tested immediately by lateral flow immunoassay
(SD-Biosensor, Korea). The STANDARD Q COVID-19 IgM/IgG
Duo Test showed according to the manufacturer’s insert this test
has a sensitivity 94% and specificity 95%. Validation of the results
was done using iFlash-SARS-CoV-2 IgG chemiluminescent
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Table 1. Comparison between high risk and low risk health care workers regarding demographic, clinical information, exposure infor-
mation, and COVID-19 like symptoms (n=455). 
Demographic characteristics                                                                            All subjects Health care workers                    p
                                                                                                                                                            High risk group     Low risk group         
                                                                                                                                                                    n=143                   n=312               
Age (mean ±SD)                                                                                                                                       32.8 ± 8.3                            33.7 ± 8                       32.4 ± 8.4              0.110
Gender (n, %)                                                                                                                                                                                                                                                                 
Male                                                                                                                                                       239 (52.5%)                       92 (64.3%)                  147 (47.1%)          0.001*  
Clinical history (n, %)                                                                                                                                                                                                                                                      
Past surgical history                                                                                                                          118 (25.9%)                       59 (41.3%)                   59 (18.9 %)          <0.001*
Past medical history                                                                                                                           89 (19.6%)                         30 (21%)                     59 (18.9%)            0.606
Hypertension                                                                                                                                         25 (5.5%)                          11(7.7%)                      14 (4.5%)             0.164
Diabetes                                                                                                                                                   9 (2.0%)                             2(1.4%)                        7 (2.2%)              0.726
Asthma                                                                                                                                                    19 (4.2%)                           8 (5.6%)                      11 (3.5%)             0.306
Allergy                                                                                                                                                      16(3.5%)                            5(3.5%)                       11 (3.5%)             0.988
Other medical conditions #                                                                                                                25 (5.5%)                          10 (7.0%)                     15 (4.8%)             0.342
Medication intake                                                                                                                               99 (21.8%)                        32 (22.4%)                    67(21.5%)             0.828
Smoking history (n, %)                                                                                                                                                                                                                                                  
Current smoker                                                                                                                                     24 (5.3%)                           5 (3.5%)                       19 (6.1%)             0.251
Ex-smoker                                                                                                                                             62 (13.6%)                        15 (10.5 %)                   47 (15.1%)            0.187
Exposure information (n, %)                                                                                                                                                                                                                                         
Direct contact with the environment where the confirmed COVID-19 was cared for       187 (41.1%)                       74 (51.7%)                  113 (36.2%)          0.002 *
History of travelling in proximity with confirmed COVID-19 patient                                       100 (22%)                          14 (9.8%)                    36 (11.5%)            0.580
Family member with COVID-19 diagnosis                                                                                       24 (5.3%)                           6 (4.2%)                       18(5.8%)              0.486
Family member with pneumonia diagnosis                                                                                    11 (2.4%)                           4 (2.8%)                       7 (2.2%)              0.747
Symptoms compatible with COVID-19 in the past 2 weeks (n, %)                                                                                                                                                                       
Flu-like illness                                                                                                                                     108 (23.7%)                        50 (35%)                     58 (18.6%)          <0.001*  
Wheezing                                                                                                                                                42 (9.2%)                         15 (10.5%)                     27(8.7%)              0.530
Fever                                                                                                                                                       61 (13.4%)                        25 (17.5%)                   36 (11.5%)            0.084
Gastroenteritis                                                                                                                                     96 (21.1%)                        34(23.8%)                    62(19.9%)             0.343
Sore throat                                                                                                                                           133 (29.2%)                       61(42.7%)                    72(23,1%)          <0.001*   
Muscle aches                                                                                                                                        81(17.8%)                         34(23.8%)                    47(15.1%)           0.024 *
IgG seroprevalence                                                                                                                                                                                                                                                          
+VE                                                                                                                                                  36 (7.9) [5.8-10.8]                       1 ,0.7                            35 ,11.2             <0.001*  










immunoassay kit (LOT 20200307; REF C86095G; YHLO
Biotech, Shenzhen). Per manufactures’ instructions, the sensitivity
and specificity of the kits were 90% and 95% respectively for IgG,
In this assay the nucleocapsid (N) protein was combined with the
spike (S) glycoprotein antigens to increase the sensitivity. The lev-
els of IgG antibodies were positively correlated with the relative
luminescence unit (RLU) and were evaluated as arbitrary units per
milliliter (AU/mL)
The study researchers via short message informed participants
who tested positive for SARS-CoV-2 antibodies.
Statistical analysis  
The researchers used the Statistical Package of Social Science
Software program (IBM SPSS Statistics for Windows, Ver. 25.0;
IBM Corp., Armonk, NY, USA). We summarized the data using
range, mean, and standard deviation for quantitative variables and
frequency and percentage for qualitative ones. We performed the
comparison between groups for qualitative variables using Chi-
square or Fisher’s exact tests, while for quantitative variables we
conducted the comparison using Independent t-test; p-values less
than 0.05 were considered statistically significant.   
Results
Between 20 /5/ 2020 and 11/6/ 2020, we screened a total num-
ber of 455 HCWs for the SARS-CoV-2 IgG antibody. Among
them, 143 (31.4%) were in the high-risk group and 312 (68,6%) in
the low-risk group. We present the demographic characteristics of
the two groups in Table 1. Out of 455 HCWs, 36 tested positive by
both IgG rapid test and chemiluminescent immunoassay; this cor-
responds to an overall seroprevalence estimate of 7.9% (95% CI
5.8 to 10.8). The prevalence of IgG against SARS-CoV2 among
the high-risk group was 1 (0.7%), in contrast, the seroprevalence
was significantly higher in the low-risk group 11% (35/312)
p<0.001. Direct contact with an environment where the confirmed
COVID-19 cared, was significantly higher in the high risk com-
pared to the low-risk group odds ratio (95% confidence interval)
OR [95% CI]: 1.9 [1.3-2.8], p<0.0001. 
The researchers also compared the subjects’ characteristics
between those with anti-SARS-CoV-2 IgG positive and negative.
Demographic data, clinical information, and smoking history were
comparable between both groups Regarding symptoms compatible
with COVID-19 in the past two weeks, 141(31%) did not report
any COVID-19 like symptoms. One third (29%) reported having a
sore throat, followed by Flu-like illness 104 (23%), and muscle
aches 82 (18%). However, there was no significant difference
between study participants who tested positive and those who were
tested negative (Table 2).
Discussion
The main outcome of the present study that the overall sero-
prevalence among HCWs is low; 7.9%. Moreover, IgG seroposi-
tivity was less prevalent among the high-risk group compared to
the low-risk group. In the current study, the seroprevalence among
HCWs was 7.9%. Consistent with the current study finding, sever-
al studies found that the seroprevalence among healthcare workers
was low and varied from 0% to 8.6% .9,10
We conducted the present study in a large non-COVID -19 uni-
versity teaching hospital aiming at predicting the real prevalence
of asymptomatic COVID-19 disease among the general popula-
tion. Interestingly, the author supposed at the start of research that
the seroprevalence would be high among HCWs. However, the
low prevalence rate among HCWs (7.9%) may suggest lower rates
among the general population. Several recent larger-scale studies
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Table 2. Association between demographic characteristics, clinical history, exposure information and COVID-19 IgG seroprevalence
(n=455).
Demographic characteristics       IgG                                                                                   p
                                                                                  +VE n=36                                      -VE n=419
Age (mean ± SD)                                                                            33.4 ± 9.3                                                      32.8 ± 8.2                                                                    0.707 
Gender (n, %)                                                                                                                                                                                                                                                    
Male                                                                                              16 (44.4%)                                                   223 (53.2%)                                                                  0.312  
Clinical history (n, %)                                                                                                                                                                                                                                       
Past surgical history (n, %)                                                    12 (33.3%)                                                   106 (25.3%)                                                                  0.291
Past medical history (n, %)                                                      8 (22.2%)                                                     81 (19.3%)                                                                   0.675
Hypertension                                                                                 2 (5.6%)                                                       23 (5.5%)                                                                    1.000
Diabetes                                                                                            0 (0)                                                            9 (2.1%)                                                                     1.000
Asthma                                                                                            1 (2.8%)                                                       18 (4.3%)                                                                    1.000
Allergy                                                                                             1 (2.8%)                                                       15 (3.6%)                                                                    1.000
Other medical conditions#                                                         3 (8.3%)                                                       22 (5.3%)                                                                    0.436
Medication intake (n, %)                                                           9 (25%)                                                       90 (21.5%)                                                                   0.623
Smoking history (n, %)                                                                                                                                                                                                                                  
Current smoker                                                                            2 (5.6%)                                                       22 (5.3%)                                                                    1.000
Ex-smoker                                                                                     6 (16.7%)                                                     56 (13.4%)                                                                   0.611
Non-smoker                                                                                 28 (77.8%)                                                   341 (81.4%)                                                                  0.596
Symptoms in the past 2 weeks (n, %)                                                                                                                                                                                                          
Flu-like illness                                                                             8 (22.2%)                                                    100 (23.9%)                                                                  0.824
Wheezing                                                                                       6 (16.7%)                                                      36 (8.6%)                                                                    0.127
Fever                                                                                              5 (13.9%)                                                     56 (13.4%)                                                                   1.000
Gastroenteritis                                                                           8 (22.2%)                                                       88 (21%)                                                                    0.863
Sore throat                                                                                    9 (25%)                                                      124 (29.6%)                                                                  0.561
Muscle aches                                                                             10 (27.8%)                                                    71 (16.9%)                                                                   0.103










documented low prevalence among the general population. The
Spanish study, which included over 60,000 participants, showed a
nationwide seroprevalence of 5.0% (population-based seroepide-
miological study).11 We got similar numbers across the 2766 par-
ticipants in the Swiss study, with seroprevalence data from Geneva
reaching 10·8%.12 All these findings from the current study and
others documented that most of the population appears to have
remained unexposed to SARS-CoV-2, even in areas with wide-
spread virus circulation.
The second main finding was that the IgG seropositivity was
more prevalent among low-risk HCWs than high risk HCW.
Inconsistent with the present study finding, a recent study conduct-
ed in Germany found that the seroprevalence was low in the high-
risk HCWs (1.2%) versus the low-risk group (5.2%).12 Out of
42,600 HCWs caring for COVID-19 patients in the second half of
the China epidemic, none was infected, suggesting that sufficient
precautions and rigorous enforcement of PPE are the major deter-
minants for eliminating COVID-19 infection,9 and consistent with
data suggesting that HCWs in hospitals involved in COVID-19
care could have a lower burden of infection than those not taking
part in COVID-19 care. 11 Contradicting results are noted in a large
study from Madrid where the SARS-CoV-2 prevalence is higher in
HCW working in areas with exposure to COVID-19 (34%) com-
pared with the low-risk area (26%) and external workers (30%) in
Madrid.13 and to a recent study conducted among frontline HCWs
during the peak of COVID-19 pandemic in a tertiary care hospital
in Egypt with higher prevalence (14.3%).14 The possible explana-
tion of the current study finding was that the high-risk group had a
high perception of increased risk of SARS- CoV-2 transmission
leading to more careful practices and more use of PPE thus, a
lower risk of acquiring the infection.14
The current study findings should be viewed with respect to
the following limitations: First, this study was limited to one hos-
pital, so its findings may not be generalizable to HCWs in other
workplaces, however, the current study was conducted to explore
the situation in this new area of inquiry. Second, detection of
SARS-CoV-2 IgG antibody in a single sample may miss any
SARS-CoV-2 infected HCW yet to seroconvert, although this is
likely to be minimal.
In conclusion, the IgG seroprevalence among the enrolled
HCWs of a tertiary non-COVID hospital in Egypt was 7.9%. The
low seropositivity against SARS CoV-2 among HCWs who have
not been exposed to COVID-19 patients suggests that we are far
behind from herd immunity.
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